Based on the article below, Who Target user of the POC resource? Gestational diabetes mellitus: Glucose management

Based on the article below, Who Target user of the POC resource? Gestational diabetes mellitus: Glucose management and maternal prognosis, Who is the Intended Patient Population INTRODUCTION — Pregnancy is generally a state of both enhanced beta-cell function and insulin resistance, mediated primarily by placental secretion of diabetogenic hormones including growth hormone, corticotropin-releasing hormone, placental lactogen (chorionic somatomammotropin), prolactin, and progesterone. These and other metabolic changes, which are most prominent in the third trimester, ensure that the fetus has an ample supply of nutrients. Gestational diabetes mellitus (GDM) develops in pregnant people whose pancreatic beta-cell function is insufficient to overcome the insulin resistance associated with the pregnant state. Among the main consequences of GDM are increased risks of preeclampsia, large for gestational age (LGA) newborns, and cesarean birth, and their associated morbidities. Patients with GDM are at high risk of developing type 2 diabetes later in life, which is not surprising since both disorders are characterized by inadequate insulin secretion in the setting of insulin resistance. In contrast to diabetes that develops pregestationally, GDM is not generally associated with an increased risk for congenital anomalies since hyperglycemia develops after organ formation is complete. There is no universally accepted standard regarding